Welcome to our dedicated page for Cumberland Pharmaceuticals SEC filings (Ticker: CPIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking how Acetadote sales stack up against Caldolor launches or when Ifetroban clears its next FDA hurdle can feel like reading a foreign language. Cumberland Pharmaceuticals’ disclosures span clinical data, patent cliffs and global royalty agreements—details that easily bury the signal inside 250-page documents. This page turns that challenge on its head by offering Cumberland Pharmaceuticals SEC filings explained simply.
Every form you need is here the moment it hits EDGAR, and Stock Titan’s AI goes to work instantly. Need the Cumberland Pharmaceuticals quarterly earnings report 10-Q filing without hunting for brand-level revenue? We surface it. Want the Cumberland Pharmaceuticals annual report 10-K simplified so patent expirations and manufacturing risks are clear? Done. Surprise licensing deal? The Cumberland Pharmaceuticals 8-K material events explained module flags it with context. Our platform pairs real-time updates with AI-powered summaries, helping professionals focused on understanding Cumberland Pharmaceuticals SEC documents with AI save hours.
Monitoring leadership moves is equally direct. Receive alerts for Cumberland Pharmaceuticals insider trading Form 4 transactions, view Cumberland Pharmaceuticals Form 4 insider transactions real-time, and drill into Cumberland Pharmaceuticals executive stock transactions Form 4 before the market reacts. Compare incentive plans inside the Cumberland Pharmaceuticals proxy statement executive compensation to pipeline milestones, or run a Cumberland Pharmaceuticals earnings report filing analysis to track cash burn versus R&D progress. From 10-K risk factors to Schedule 13D activism, our comprehensive coverage and expert commentary keep you ahead—no more wading through jargon to find what matters.
Cumberland Pharmaceuticals (CPIX) filed its Q3 2025 report, showing quarterly net revenue of
Sancuso delivered
Operating cash flow turned positive at
After quarter end, Cumberland and RedHill formed a joint company to co‑commercialize Talicia in the U.S., with Cumberland committing
Cumberland Pharmaceuticals (CPIX) — insider share acquisitions reported. Director Caroline Young disclosed a series of automatic purchases executed under a Rule 10b5-1 trading plan.
The filing lists acquisitions of 6 shares on multiple trading days from October 1–31, 2025, at prices ranging from $3.14 to $3.63. Following the final reported transaction on October 31, 2025, the director beneficially owned 33,168 shares, held directly. The transactions were made pursuant to a 10b5-1 plan adopted on November 14, 2024.
Cumberland Pharmaceuticals (CPIX) director James Jones reported automatic open‑market purchases under a Rule 10b5‑1 trading plan. The filings show purchases of 13 shares on each trading day from October 1–31, 2025, at prices ranging from $3.14 to $3.63. Following these transactions, Jones beneficially owns 44,491 shares, held direct.
The Rule 10b5‑1 plan was adopted on November 14, 2024. No derivative securities were reported.
Cumberland Pharmaceuticals (CPIX) reported insider acquisitions by Chairman & CEO A.J. Kazimi on a Form 4. The filing lists a series of 13-share purchases on multiple days from 10/01/2025 through 10/31/2025, executed under a Rule 10b5-1 trading plan.
Reported prices ranged from $3.14 to $3.63 per share across the period. Following the latest transaction, Kazimi’s direct beneficial ownership is 5,700,583 shares.
Cumberland Pharmaceuticals (CPIX) director reported a series of open‑market purchases executed automatically under a Rule 10b5-1 trading plan adopted on November 14, 2024. The transactions occurred on multiple trading days from October 1 to October 31, 2025, with 68 shares acquired each day at prices generally in the $3.14–$3.63 range.
Following these purchases, the reporting person’s directly held stake was 292,595 shares as of October 31, 2025. The filing indicates it was made by a single reporting person serving as a Director, with all holdings shown as Direct (D).
Cumberland Pharmaceuticals (CPIX) reported a strategic arrangement with RedHill Biopharma to jointly commercialize Talicia, an FDA-approved oral capsule for treating Helicobacter pylori infection in adults. The product targets a bacterial infection that is a leading risk factor for gastric cancer.
The company furnished a related press release as Exhibit 99.1 dated October 21, 2025. This update was disclosed under Item 8.01 (Other Events).
Caroline Young, a director of Cumberland Pharmaceuticals Inc (CPIX), reported a sequence of open-market purchases of common stock executed under a Rule 10b5-1 trading plan adopted on November 14, 2024. Purchases occurred on multiple dates from 09/02/2025 through 09/30/2025, with reported per-share prices ranging from $3.05 to $3.60. After the final reported trade on 09/30/2025, the filing shows 33,030 shares beneficially owned by Ms. Young.
The transactions were automatic under the disclosed 10b5-1 plan; the filing is signed by an attorney-in-fact on behalf of Ms. Young and contains no derivative transactions or other compensatory awards. All information is limited to the trades listed and the plan adoption date disclosed in the explanation section.
James Jones, a director of Cumberland Pharmaceuticals Inc (CPIX), reported a series of open-market purchases of common stock executed under a Rule 10b5-1 trading plan adopted on November 14, 2024. The transactions occurred daily from September 2, 2025 through September 30, 2025, with reported per-share prices ranging from $3.05 to $3.60. After the final reported purchase on September 30, 2025, the filing shows 44,192 shares beneficially owned by the reporting person. All transactions are reported as acquisitions and are marked as direct ownership.
A.J. Kazimi, Chairman and CEO of Cumberland Pharmaceuticals Inc. (CPIX), reported a series of open-market purchases executed under a Rule 10b5-1 trading plan adopted on November 14, 2024. The reported transactions occurred between September 2, 2025 and September 30, 2025, with incremental buys at prices ranging from $3.05 to $3.60. Following the transactions, the filing shows beneficial ownership of 5,700,284 shares. The Form 4 was signed by an attorney-in-fact, John Hamm, on October 3, 2025. The filing identifies the reporting person as a Director, 10% owner, and Chairman and CEO.
FAQ
What is the current stock price of Cumberland Pharmaceuticals (CPIX)?
What is the market cap of Cumberland Pharmaceuticals (CPIX)?
